DE602004003751D1 - Heterocyclische Oximderivate, Verfahren zu ihrer Herstellung und Verwendung in der Behandlung von Typ II Diabetes - Google Patents

Heterocyclische Oximderivate, Verfahren zu ihrer Herstellung und Verwendung in der Behandlung von Typ II Diabetes

Info

Publication number
DE602004003751D1
DE602004003751D1 DE602004003751T DE602004003751T DE602004003751D1 DE 602004003751 D1 DE602004003751 D1 DE 602004003751D1 DE 602004003751 T DE602004003751 T DE 602004003751T DE 602004003751 T DE602004003751 T DE 602004003751T DE 602004003751 D1 DE602004003751 D1 DE 602004003751D1
Authority
DE
Germany
Prior art keywords
diabetes
preparation
treatment
type
oxime derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004003751T
Other languages
English (en)
Other versions
DE602004003751T2 (de
Inventor
Veronique Leclerc
Sylvie Pailloux
Pascal Carato
Carine Introvigne
Nicolas Lebegue
Pascal Berthelot
Catherine Dacquet
Jean Albert Boutin
Daniel Henri Caignard
Pierre Renard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires Servier SAS
Original Assignee
Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Servier SAS filed Critical Laboratoires Servier SAS
Publication of DE602004003751D1 publication Critical patent/DE602004003751D1/de
Application granted granted Critical
Publication of DE602004003751T2 publication Critical patent/DE602004003751T2/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
DE602004003751T 2003-07-28 2004-07-27 Heterocyclische Oximderivate, Verfahren zu ihrer Herstellung und Verwendung in der Behandlung von Typ II Diabetes Active DE602004003751T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0309214A FR2858321B1 (fr) 2003-07-28 2003-07-28 Nouveaux derives d'oximes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR0309214 2003-07-28

Publications (2)

Publication Number Publication Date
DE602004003751D1 true DE602004003751D1 (de) 2007-02-01
DE602004003751T2 DE602004003751T2 (de) 2007-10-18

Family

ID=33523001

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004003751T Active DE602004003751T2 (de) 2003-07-28 2004-07-27 Heterocyclische Oximderivate, Verfahren zu ihrer Herstellung und Verwendung in der Behandlung von Typ II Diabetes

Country Status (31)

Country Link
US (1) US7071221B2 (de)
EP (1) EP1502590B1 (de)
JP (1) JP4406331B2 (de)
KR (1) KR100677013B1 (de)
CN (1) CN100497323C (de)
AR (1) AR045125A1 (de)
AT (1) ATE348612T1 (de)
AU (1) AU2004203454B2 (de)
BR (1) BRPI0403028A (de)
CA (1) CA2475137C (de)
CY (1) CY1106336T1 (de)
DE (1) DE602004003751T2 (de)
DK (1) DK1502590T3 (de)
EA (1) EA007718B1 (de)
EG (1) EG24967A (de)
ES (1) ES2279310T3 (de)
FR (1) FR2858321B1 (de)
GE (1) GEP20063896B (de)
HK (1) HK1071748A1 (de)
HR (1) HRP20070117T8 (de)
MA (1) MA27104A1 (de)
MX (1) MXPA04007257A (de)
MY (1) MY139278A (de)
NO (1) NO327257B1 (de)
NZ (1) NZ534334A (de)
PL (1) PL1502590T3 (de)
PT (1) PT1502590E (de)
SG (1) SG109010A1 (de)
SI (1) SI1502590T1 (de)
UA (1) UA80814C2 (de)
ZA (1) ZA200405893B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101360736A (zh) * 2005-11-23 2009-02-04 阿斯利康(瑞典)有限公司 L-丙氨酸衍生物
FR2894965B1 (fr) * 2005-12-20 2008-01-25 Servier Lab Nouveaux derives d'oximes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2898125B1 (fr) * 2006-03-06 2008-06-13 Servier Lab Nouveaux derives heterocycliques cycloalkyles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2007141473A1 (en) * 2006-06-09 2007-12-13 Astrazeneca Ab N-(benzoyl)-o- [2- (pyridin- 2 -ylamino) ethyl] -l-tyrosine derivatives and related compounds as a5b1 antagonists for the treatment of solid tumors
FR2903404B1 (fr) * 2006-07-10 2008-08-22 Servier Lab Nouveaux derives tetracycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2008093065A1 (en) * 2007-01-29 2008-08-07 Astrazeneca Ab L-ALANINE DERIVATIVES AS α5βL ANTAGONISTS
WO2008125811A1 (en) * 2007-04-11 2008-10-23 Astrazeneca Ab N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS
US9193767B2 (en) 2011-03-30 2015-11-24 Brown University Enopeptins, uses thereof, and methods of synthesis thereto
WO2016037072A2 (en) * 2014-09-04 2016-03-10 Brown University Enopeptin analogas and methods of use thereof
CN104725367B (zh) * 2015-03-13 2017-06-23 三峡大学 四氢苯并噻唑‑7‑酮肟药物，制备方法及其应用
CN104788436B (zh) * 2015-03-13 2018-05-01 三峡大学 四氢苯并呋喃-4-酮肟基三唑药物，制备方法及其应用
EP3509590A4 (de) 2016-09-07 2020-12-02 Pliant Therapeutics, Inc. N-acyl-aminosäure-verbindungen und verfahren zur verwendung

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US32769A (en) * 1861-07-09 Beehive
US4228292A (en) * 1978-07-20 1980-10-14 Monsanto Company N-Substituted benzothiazolines and benzoxazolines and their use as herbicides and plant growth regulants
EP0022317B1 (de) * 1979-06-12 1983-09-21 Fujisawa Pharmaceutical Co., Ltd. 2-Oxo-benzothiazolin-, Benzoxazolin- oder Indolin-Derivate, deren Herstellung und derartige Verbindungen enthaltende pharmazeutische Zusammensetzungen
CN1103590C (zh) * 1993-09-15 2003-03-26 三共株式会社 使用噻唑烷二酮防止或延缓非胰岛素依赖性糖尿病(niddm)的发作
SK111195A3 (en) * 1994-09-13 1997-06-04 Sandoz Technology Ltd Bicyclic ethers substituted with oxazole and thiazole, process for producing thereof and pharmaceutical composition containing same
FR2804431A1 (fr) * 2000-02-02 2001-08-03 Adir Nouveaux derives heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP1277729A4 (de) * 2000-04-28 2005-05-11 Sankyo Co Ppar-g(g)-modulatoren
FR2830012B1 (fr) * 2001-09-21 2003-10-31 Servier Lab Nouveaux derives heterocycliques, leur procede de preparation et les compositions pharamaceutiques qui les contiennent

Also Published As

Publication number Publication date
EA200400867A2 (ru) 2005-02-24
EG24967A (en) 2011-03-13
CY1106336T1 (el) 2011-10-12
US20050026973A1 (en) 2005-02-03
ATE348612T1 (de) 2007-01-15
EA007718B1 (ru) 2006-12-29
MXPA04007257A (es) 2005-03-31
ES2279310T3 (es) 2007-08-16
NZ534334A (en) 2005-12-23
EP1502590A1 (de) 2005-02-02
EP1502590B1 (de) 2006-12-20
ZA200405893B (en) 2005-01-24
BRPI0403028A (pt) 2005-06-14
UA80814C2 (en) 2007-11-12
FR2858321A1 (fr) 2005-02-04
CN100497323C (zh) 2009-06-10
JP2005047919A (ja) 2005-02-24
KR20050013514A (ko) 2005-02-04
AU2004203454A1 (en) 2005-02-17
NO327257B1 (no) 2009-05-25
CA2475137A1 (fr) 2005-01-28
HRP20070117T3 (en) 2007-04-30
GEP20063896B (en) 2006-08-10
CA2475137C (fr) 2010-04-06
NO20043188L (no) 2005-01-31
KR100677013B1 (ko) 2007-01-31
MY139278A (en) 2009-09-30
JP4406331B2 (ja) 2010-01-27
DE602004003751T2 (de) 2007-10-18
AR045125A1 (es) 2005-10-19
US7071221B2 (en) 2006-07-04
AU2004203454B2 (en) 2010-05-27
SI1502590T1 (sl) 2007-04-30
PT1502590E (pt) 2007-02-28
SG109010A1 (en) 2005-02-28
FR2858321B1 (fr) 2006-01-20
HK1071748A1 (en) 2005-07-29
CN1590379A (zh) 2005-03-09
HRP20070117T8 (en) 2007-07-31
DK1502590T3 (da) 2007-04-10
MA27104A1 (fr) 2004-12-20
EA200400867A3 (ru) 2005-04-28
PL1502590T3 (pl) 2007-04-30

Similar Documents

Publication Publication Date Title
DE602004029236D1 (de) Cyclische harnstoffderivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung als kinaseinhibitoren
DE502004008951D1 (de) Glucopyranosyloxy-pyrazole, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
DE502005007840D1 (de) 7-phenylamino-4-chinolon-3-carbonsäure-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
ATE518841T1 (de) Herstellung und verwendung von arylalkylsäurederivaten zur behandlung von obesitas
ATE407926T1 (de) Krystallinform beta von ivabradine-hydrochlorid, verfahren zu dessen herstellung und diesen enthaltende pharamazeutische zusammensetzung
ATE265424T1 (de) Acylphenylharnstoffderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
ATE557013T1 (de) Glucopyranosyl-substituierte benzol-derivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
DE602006019731D1 (de) 2,6-chinolinderivate sowie verfahren zu ihrer herstellung und verwendung als arzneimittel
DE50310783D1 (de) Neue thiophenglycosidderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
DE602004003751D1 (de) Heterocyclische Oximderivate, Verfahren zu ihrer Herstellung und Verwendung in der Behandlung von Typ II Diabetes
DE60307766D1 (de) Gewürzmittel und Verfahren zu seiner Herstellung
DE502004008024D1 (de) Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, ihre verwendung und verfahren zu ihrer herstellung
ATE323092T1 (de) Pyridopyrimidinon-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen
DE602005014280D1 (de) Verfahren zur herstellung von ä1,4,5ü-oxadiazepinderivaten
DE60306693D1 (de) Heterozyklische Verbindungen enthaltende opthalmische Gegenstände und Verfahren zu deren Herstellung
DE602006016285D1 (de) Derivate von 4,5-diarylpyrrol, verfahren zu deren herstellung und deren verwendung in therapeutika
DE60327388D1 (de) Selbstinversierender inverser Microlatex, Verfahren zu seiner Herstellung und Verwendung
ATE366731T1 (de) Pyrrolidin- und thiazolidin-derivate, deren darstellung und anwendung zur behandlung von hyperglykämie und typ ii diabetes
DE50011179D1 (de) Aminocarbonyl-substituierte benzimidazolderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE50210216D1 (de) Luftsackgewebe, Verfahren zu seiner Herstellung und Verwendung
DE602005005355D1 (de) 9-Chloro-15-deoxyprostaglandinderivate, Verfahren zu ihrer Herstellung und deren Verwendung als Medikamente
ATE487706T1 (de) Cyclische n-ä1,3,4ü-thiadiazol-2-yl- benzsulfonamide, verfahren zu deren herstellung und deren verwendung als arzneimittel
DE112006000999A5 (de) Formyltetrahydrophyrane, Verfahren zu ihrer Herstellung sowie ihre Verwendung in der Herstellung von Flüssigkristallinen Verbindungen
DE502004002124D1 (de) Sio2-formkörper, verfahren zu ihrer herstellung und verwendung
DE602004015726D1 (de) Acylaminothiazolderivate, verfahren zu deren herstellung und deren verwendung als inhibitoren der produktion von beta-amyloidpeptid

Legal Events

Date Code Title Description
8364 No opposition during term of opposition